Emergency authorization of medical products: Regulatory challenges from the 2009 H1N1 influenza pandemic in Japan

Biosecurity and Bioterrorism

Volumn 10, Issue 4, 2012, Pages 372-382

  Urushihara, Hisashi ^a   Matsui, Sayako ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; INFLUENZA VACCINE; PERAMIVIR;

ARTICLE; DRUG APPROVAL; EMERGENCY; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; JAPAN; LEGAL ASPECT; PANDEMIC; UNITED STATES;

ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG APPROVAL; EMERGENCIES; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; PANDEMICS; UNITED STATES;

EID: 84871388677     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2012.0017     Document Type: Article

References (56)

1. Chan M. World now at the start of 2009 influenza pandemic. http://www.who.int/mediacentre/news/statements/2009/h1n1-pandemic-phase6- 20090611/en/index.html. Accessed May 15, 2012.
2. US Department of Health and Human Services, Food and Drug Administration. Authorization of emergency use of the antiviral product peramivir accompanied by emergency use information Fed Regist Nov 2, 2009;74:56644-56649. http://www.gpo.gov/fdsys/granule/FR-2009-11-02/E9-26291/content-detail.html. Accessed September 26, 2012.
3. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med Dec 3, 2009;361(23):2204-2207.
4. US Department of Health and Human Services. Determination and declaration regarding emergency use of anthrax vaccine adsorbed for prevention of inhalation anthrax. Fed Regist Feb 2, 2005;70:5450-5451.
5. Nightingale SL, Prasher JM, Simonson S. Emergency use authorization (EUA) to enable use of needed products in civilian and military emergencies, United States. Emerg Infect Dis 2007;13(7):1046-1051. (Pubitemid 47048077)
6. US Department of Health and Human Services, Food and Drug Administration. Authorizations of emergency use of certain antiviral drugs-zanamivir and oseltamivir phosphate. Fed Regist Aug 4, 2009;74:38648-38654.
7. US Department of Health and Human Services. Determination and declarations regarding emergency use of certain in vitro diagnostic, antiviral, and personal respiratory products accompanied by emergency use information. Fed Regist Aug 4, 2009;74:38628-38630.
8. Sherman SE, Foster J, Vaid S. Emergency use authority and 2009 H1N1 influenza. Biosecur Bioterror 2009;7(3):245-250.
9. The Novel Influenza Task Force, headed by Japanese Prime Minister. Basic policies on how to deal with novel influenza [in Japanese]. October 1, 2009.
10. Urushihara H, Doi Y, Arai M, et al. Oseltamivir prescription and regulatory actions vis-a-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PLoS ONE 2011;6(12):e28483.
11. The Novel Influenza Task Force, headed by Japanese Prime Minister. Basic policy of vaccination for novel influenza A/H1N1 [in Japanese]. October 1, 2009.
12. Pharmaceutical Affairs Law. Law No. 145 of 1960. Final revisions. Tokyo: Government of Japan; June 21, 2006.
13. Act Concerning Measures for Protection of the People in Armed Attack Situations, etc. Act No. 112 of 2004. Tokyo: Government of Japan; June 18, 2004.
14. Ministry of Health, Labour and Welfare Health Crisis Management. Basic guidelines [in Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 1997.
15. The action program for countermeasures to novel influenza [in Japanese]. February 2009 amendment ed: Conference of relevant ministries and agencies on countermeasures to novel and avian influenza; 2009.
16. Department of Communicable Disease, Surveillance and Response, Global Influenza Programme. WHO global influenza preparedness plan. Geneva: World Health Organization; 2005.
17. Kawakami K. Countermeasures for infectious diseases and vaccine administration [in Japanese]. Pharmacia 2008;44(7): 693-696.
18. US Food and Drug Administration, Office of Counterterrorism Policy and Planning. Guidance-Emergency Use Authorization ofMedical Products. 2007. http://www.fda.gov/RegulatoryInformation/Guidances/ucm125127.htm. Accessed October 1, 2012.
19. Ray J. Federal declaration of a public health emergency. Biosecur Bioterror 2009;7(3):251-258.
20. Cabinet Order on Drugs and Medical Devices Specified by Cabinet Order Pursuant to the Provision of Pharmaceutical Affairs Law Article 14-3 Paragraph 1 (November 11, 2009) [in Japanese]. Tokyo: Cabinet Office; 2009.
21. Review report on emergency approval of Arepanrix (H1N1) intramuscular injection [in Japanese]. Tokyo: Pharmaceuticals and Medical Devices Agency; November 25, 2009.
22. Common technical documents for the registration of pharmaceuticals for human use for emergency approval of cellcultured H1N1 antigen containing influenza vaccine "Novartis," intramuscular injection suspension [in Japanese]. Tokyo: Novartis Pharma K.K.; November 6, 2009.
23. Johnson CE. Determination that a public health emergency exists. April 26, 2009. http://www.flu.gov/planningpreparedness/federal/h1n1emergency042609. html. Accessed May 12, 2012.
24. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. Clin Infect Dis Mar 15 2011;52(6):695-706.
25. US Department of Health and Human Services, Food and Drug Administration. Expanded access to investigational drugs for treatment use. 21 CFR 312, 21 CFR 316. Fed Regist Aug 13, 2009;74:40900-40945.
26. Common technical documents for the registration of pharmaceuticals for human use for emergency approval of Arepanrix H1N1 intramuscular injection [in Japanese]. Tokyo: GlaxoSmithKline K.K.; October 16, 2009.
27. ICH harmonised tripartite guideline M4: organisation of the common technical document for the registration of pharmaceuticals for human use. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; July 1, 2003.
28. ICH harmonised tripartite guideline E5(R1): ethnic factors in the acceptability of foreign clinical data. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; February 5, 1998.
29. Arepanrix H1N1 intramuscular injection, emergency approval package insert [in Japanese]. 1st ed. Tokyo: Glaxo-SmithKline K.K.; 2010.
30. Cell-cultured H1N1 antigen containing influenza vaccine "Novartis," intramuscular injection suspension, emergency approval package insert [in Japanese]. 1st ed. Tokyo: Novartis Pharma K.K.; 2010.
31. Emergency use authorization of peramivir iv. Fact sheet for health care providers. US Food and Drug Administration; 2009.
32. Review report on emergency approval of cell-cultured H1N1 antigen containing influenza vaccine "Novartis," intramuscular injection suspension [in Japanese]. Tokyo: Pharmaceuticals and Medical Devices Agency; December 22, 2009.
33. Arya V, Carter WW, Robertson SM. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. Clin Pharmacol Ther 2010;88(5):587-589.
34. Results of public comment on emergency approval of imported novel influenza vaccines (Feburary 22, 2010) [in Japanese]. Tokyo: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour, and Welfare; 2010.
35. Implementation guidelines for vaccination program of novel influenza A/H1N1 vaccines (October 13, 2009) [in Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2009.
36. Pamphlet explaining comparison between imported and domestic vaccines [in Japanese]. Ministry of Health, Labour and Welfare; February 10, 2010.
37. Hollister AS, Sheridan WP. The emergency use authorization of peramivir IV: a view from the manufacturer. Clin Pharmacol Ther 2011;89(2):172-174.
38. Murphy M. BioCryst: Israel orders 150 doses of H1N1 antiviral peramivir. Seeking Alpha December 21, 2009. http://seekingalpha.com/article/179144- biocryst-israel-orders-150-doses-of-h1n1-antiviral-peramivir. Accessed April 27, 2012.
39. BioCryst receives first peramivir order from U.S. government [press release]. Durham, NC: BioCryst Pharmaceuticals, Inc.; November 5, 2009.
40. Yu Y, Garg S, Yu PA, et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis 2012 Jul;55(1):8-15.
41. Transition of novel A/H1N1 influenza to seasonal one in influenza response program (March 18, 2011) [in Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2011.
42. Number of people vaccinated and reporting frequencies of adverse reactions. 4th Investigation Committee of Safety Measurements (August 25, 2010) [in Japanese]. Tokyo: Subcommittee on Safety Measurement, Committee of Safety of Drugs, Pharmaceutical Affairs and Food Sanitation Council, Ministry of Health, Labour and Welfare; 2010.
43. Hamburg M. Termination of declarations justifying emergency use authorizations of certain in vitro diagnostic devices, antiviral drugs, and personal respiratory protection devices. Fed Regist June 25, 2010;75:36432-36435.
44. US National Institutes of Health. ClinicalTrials.gov 2011. http://clinicaltrials.gov/ct2/home. AccessedNovember 29, 2011.
45. Discussion points on legal system necessary for countermeasures to novel influenza [in Japanese]. Cabinet Secretariat Office for Countermeasures to Novel Influenza and the Like; November 10, 2011.
46. Shionogi announces positive results from Phase 3 studies of peramivir, a novel anti-viral drug for influenza [press release]. Tokyo: Shionogi & Co., Ltd.; July 17, 2009.
47. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011 Nov;55(11):5267-5276.
48. Review report on rapiacta 300 mg bag for intravenous drip infusion and rapiacta 150 mg vial for intravenous drip infusion [in Japanese]. Tokyo: Pharmaceuticals and Medical Devices Agency; December 16, 2009.
49. The Novel Influenza Task Force, Japanese Association of Infectious Diseases. Review of year of 2010 and point of view on 2010/2011 season [in Japanese]. Tokyo: Japanese Association of Infectious Diseases; December 3, 2010.
50. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect 2011 Oct; 63(4):288-294.
51. Okabe N. Review of novel influenza (pandemic 2009) and status of avian influenza (A/H5N1) [in Japanese]. Infectious Disease Surveillance Center, National Institute of Infectious Disease; November 6, 2011.
52. Quinn SC, Kumar S, Freimuth VS, Kidwell K, Musa D. Public willingness to take a vaccine or drug under emergency use authorization during the 2009 H1N1 pandemic. Biosecur Bioterror 2009;7(3):275-290.
53. Tsubouchi M, Matsui S, Banno Y, Kurokawa K, Kawakami K. Overview of the clinical application of regenerative medicine products in Japan. Health Policy 2008 Oct;88(1):62-72.
54. Pavia AT. Editorial commentary: what did we learn from the emergency use authorization of peramivir in 2009? Clin Infect Dis 2012 Jul;55(1):16-18.
55. Woodcock J. Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Ther 2012 Mar;91(3):378-380.
56. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012 Mar;91(3):426-437.